Login or Register to make a submission.

Submission Preparation Checklist

As part of the submission process, authors are required to check off their submission's compliance with all of the following items, and submissions may be returned to authors that do not adhere to these guidelines.
  • The submission has not been previously published, nor is it before another journal for consideration (or an explanation has been provided in Comments to the Editor).
  • The submission file is in OpenOffice, Microsoft Word, or RTF document file format.
  • Where available, URLs for the references have been provided.
  • The text is single-spaced; uses a 12-point font; employs italics, rather than underlining (except with URL addresses); and all illustrations, figures, and tables are placed within the text at the appropriate points, rather than at the end.
  • The text adheres to the stylistic and bibliographic requirements outlined in the Author Guidelines.

Author Guidelines

Fees and funding

Article-processing charges

The journal of Molecular and Cellular Therapies is an open access journal with costs. The article-processing charge of MCT is $1200/ £920/€1050 for each article accepted for publication. The charges can be waived or discounted on a case-by-case basis. Authors can request a waiver or discount during the submission process. For further details, contact with the Office of Molecular and Cellular Therapies directly.

 

Language editing services

All authors have to ensure the English language of submitted manuscript to Molecular and Cellular Therapies, with sufficient quality to be understood. If you need help with writing in English you should consider, please contact with the Office of Molecular and Cellular Therapies directly.

 

Copyright

Copyright on any open access article in Molecular and Cellular Therapies published by the Institute is retained by the author(s).Authors can grant any third party the right to use the article freely as long as its integrity is maintained and its original authors, citation details and publisher are identified. Please contact the Office of Molecular and Cellular Therapies for more information specifically regarding permissions if there are questions.

 

Preparing your manuscript

Molecular and Cellular Therapies publishes the following article types:

1.  Research Article Preparing: Please refer the publication style of Clinical and Translational Medicine (clintransmed.springeropen.com) published by Springer-Nature Publisher.

Title page: The title page should include the title, the full names, institutional addresses and email addresses for all authors, and the full information of the corresponding author.

Abstract: The abstract should be less than360 words, with minimized use of abbreviations and without cite references. The abstract must include Background with aims, Results with main findings, and Conclusions.

Keywords:Please provide 5-6 keywords representing the main content of the article.

Background: The Background section should explain the background to the study, its aims, a summary of the existing literature and aims of designed study.

Methods: The methods should includedesign and setting of the study, participants, materials, all processes, interventions and comparisons, as well as statistical analysis used.

Results:The Results should include the main findings of the study, statistical analysis, and tables and figures.

Discussion:The Discussion should include the implications of the findings, highlight outstanding points and limitations of the study, explain study protocols and methodology, and future potentials and indications.

Conclusions:The Conclusion should include a clear summary of main findings, emphasize the importance and relevance of the study to the application, and indicate future potentials.

Abbreviations: All abbreviations used in the text they should be defined in the text at first appearance, and a list of abbreviations should be provided.

Ethics:Ethics approval and consent should be clearly addressed in the text. Manuscripts involving human participants, human data or human tissue mustinclude a statement on ethics approval and consent (even where the need for approval was waived) and the name of the ethics committee that approved the study and the committee’s reference number. Studies involving animals must include a statement on ethics approval.

Competing interests: All financial and non-financial competing interests must be declared in this section.

Funding: All sources of funding for the research reported should be declared.

Authors' contributions: The section should clarify the individual contributions of each author to the study.

Acknowledgements: The section should describe the appreciation for one who helps the article, with the permission from all those mentioned in the Acknowledgements section.

Authors' information: The section requests each author provide the name, academic title, affiliation, brief description of research projects, and outstanding contributions made. Authors’ information will be listed in a separate Experts section of home page.

References: Please refer thereference style of Clinical and Translational Medicine (clintransmed.springeropen.com) published by Springer-Nature Publisher as following:

  • Article within a journal: Smith JJ. The world of science. Am J Sci. 1999;36:234-5.
  • Article within a journal (no page numbers): Rohrmann S, Overvad K, Bueno-de-Mesquita HB, Jakobsen MU, Egeberg R, Tjønneland A, et al. Meat consumption and mortality - results from the European Prospective Investigation into Cancer and Nutrition. BMC Medicine. 2013;11:63.
  • Article within a journal by DOI: Slifka MK, Whitton JL. Clinical implications of dysregulated cytokine production. Dig J Mol Med. 2000; doi:10.1007/s801090000086.
  • Article within a journal supplement: Frumin AM, Nussbaum J, Esposito M. Functional asplenia: demonstration of splenic activity by bone marrow scan. Blood 1979;59Suppl 1:26-32.
  • Book chapter, or an article within a book: Wyllie AH, Kerr JFR, Currie AR. Cell death: the significance of apoptosis. In: Bourne GH, Danielli JF, Jeon KW, editors. International review of cytology. London: Academic; 1980. p. 251-306.
  • OnlineFirst chapter in a series (without a volume designation but with a DOI): Saito Y, Hyuga H. Rate equation approaches to amplification of enantiomeric excess and chiral symmetry breaking. Top Curr Chem. 2007. doi:10.1007/128_2006_108.
  • Complete book, authored: Blenkinsopp A, Paxton P. Symptoms in the pharmacy: a guide to the management of common illness. 3rd ed. Oxford: Blackwell Science; 1998.
  • Online document: Doe J. Title of subordinate document. In: The dictionary of substances and their effects. Royal Society of Chemistry. 1999. http://www.rsc.org/dose/title of subordinate document. Accessed 15 Jan 1999.
  • Online database: Healthwise Knowledgebase. US Pharmacopeia, Rockville. 1998. http://www.healthwise.org. Accessed 21 Sept 1998.
  • Supplementary material/private homepage: Doe J. Title of supplementary material. 2000. http://www.privatehomepage.com. Accessed 22 Feb 2000.

2. Review/Mini-review

All review/mini-review articles are invited by the Editorial Board of Molecular and Cellular Therapies and should meet the following criteriawithin the scope of Molecular and Cellular Therapies:

  • Focus on the latest and front-line science and topics
  • Discuss certain areas and topics with multi-opinions and comments
  • Analyze the progress in specified areas
  • Present systemic figures and full picture of specified molecules or cells

Review article is expected to be less than 6000 words, 8 figures, and 100 references.

3.  Editorial/Perspective/Commentaries

Editorials/Perspectives/Commentariesbring the most attention on important issues, topics, and areas, promote the discussion either by the phrasing of new hypotheses, alternative interpretations of existing work, or by the presentation of new proposals for tackling existing problems.Commentaries should be short and narrowly focused on contemporary interest. Editorials/Perspectives/Commentaries are mostly invited and should be no longer than 1500 words, 1 figure, and 10 references.

4.  Case Report/Short Communication

Case Report/Short Communicationwill publish original and interesting case reports or short research data that contribute significantly to medical knowledge.Manuscripts should present unusual side effects or adverse interactions, unusual presentations of a disease, or new light on the possible pathogenesis of a disease.Case Report/Short Communication should be no longer than 2000, 3 figures, and 30 references.